Conflict of interest
S.N. received Honoraria from Mitsubishi Tanabe Pharma, EA Pharma Co., Ltd., Janssen Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., and AbbVie Inc., and has received research funding from Mitsubishi Tanabe Pharma. M.W. received research funding from Shire, a Takeda company. T.M. received research funding from Shire International GmbH, Takeda Pharmaceuticals; Asahi Kasei Pharma; Taiho Pharmaceutical; Chugai Pharmaceutical; Yakult Honsha; Eli Lilly Japan; Ono Pharmaceutical; Sanofi; Kaken Pharmaceutical; and Mitsubishi Tanabe Pharma; and holds a chair endowed by Kinshukai Medical Corporation. E.U. and R.K.S. are employees of Takeda Pharmaceutical Company Limited, Tokyo, Japan. M.Y. and S.C. are employees of Takeda Pharmaceutical Company, Cambridge, MA, USA. A.G. was a former employee of Shire Human Genetic Therapies, Inc., a Takeda company, MA, USA. A.S., Y.T., H.O., and H.I. have no conflicts to disclose.